

FDA Staff Manual Guides, Volume I - Organizations and Functions

Department of Health and Human Services

Food and Drug Administration

Center for Drug Evaluation and Research

Office of New Drugs

Office of Cardiology, Hematology, Endocrinology & Nephrology

Division of Diabetes, Lipid Disorders & Obesity

Effective Date: September 25, 2019

1. Division of Diabetes, Lipid Disorders & Obesity (DCDGBA).

- A. Reviews Investigational New Drugs and requests for claimed investigational exemption regulated by this Division and decides on appropriate regulatory action. Develops policies and procedures pertinent to particular aspects of investigation of drugs and biologics.
- B. Evaluates New Drug Applications (NDAs) and Biologics License Applications (BLAs) for safety and effectiveness and formulates decisions or recommendations regarding approvability in accord with applicable regulations/statutes. Evaluates supplements that propose changes in the conditions upon which NDA/BLA approvals are based. Develops regulatory and scientific policies and procedures applicable to the review and evaluation of drugs and biologics for diabetes, lipid disorders, and obesity.
- C. Evaluates adequacy of information in proposed labeling for diabetes, lipid disorders, and obesity products.
- D. Evaluates and takes appropriate action on recommendations concerning withdrawal of approval of NDAs and BLAs for diabetes, lipid disorders, and obesity products.
- E. Provides advice and information to other components of the Center and to the Food and Drug Administration (FDA) on drugs for the treatment of diabetes, lipid disorders, and obesity with respect to medical and scientific issues, status of


drug and biologics applications, appropriate policy, and proposed regulatory actions.

- F. Utilizes the advisory committee process to obtain advice on product safety and effectiveness. Also participates in FDA sponsored consumer and professional educational programs on drug standards.
- G. Develops, in coordination with other FDA components, guidance for staff, sponsors and the public that describes the FDA's interpretation of, or policy on, regulatory issues for diabetes, lipid disorders, and obesity products.
- H. Performs medical and scientific evaluations of submissions on generic drugs, drugs under monograph, and Over-the-Counter drug products regulated by other offices in the Center, as applicable.

2. Authority and Effective Date.

The functional statements for the Division of Diabetes, Lipid Disorders & Obesity were approved by the Secretary of Health and Human Services on September 25, 2019.

**Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of New Drugs
Office of Cardiology, Hematology, Endocrinology & Nephrology
Division of Diabetes, Lipid Disorders & Obesity**



Staff Manual Guide 1263.31
Organizations and Functions
Effective Date: September 25, 2019

The following is the Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of New Drugs, Office of for Cardiology, Hematology, Endocrinology & Nephrology, Division of Diabetes, Lipid Disorders, & Obesity organization structure depicting all the organizational structures reporting to the Director.

Division of Diabetes, Lipid Disorders, & Obesity (DCDGBA).